{"id":15020,"date":"2020-01-20T09:22:06","date_gmt":"2020-01-20T14:22:06","guid":{"rendered":"https:\/\/medicarereport.org\/?p=15020"},"modified":"2020-01-20T09:22:06","modified_gmt":"2020-01-20T14:22:06","slug":"patients-still-struggle-to-balance-high-costs-of-ms-treatment-despite-generic","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=15020","title":{"rendered":"Patients Still Struggle To Balance High Costs Of MS Treatment, Despite Generic"},"content":{"rendered":"<p>(By Sydney Lupkin for NPR)<\/p>\n<p>Sometimes, the approval of a new generic drug offers more hype than hope for patients&#8217; wallets, as people with multiple sclerosis know all too well. New research shows just how little the introduction of a generic version of Copaxone \u2014 one of the most popular MS drugs \u2014 did to lower their medicine costs.\u00a0 Continue reading article <a href=\"https:\/\/www.npr.org\/sections\/health-shots\/2020\/01\/20\/797477657\/patients-still-struggle-to-balance-high-costs-of-ms-treatment-despite-generic\">here&#8230;<\/a><\/p>\n<p><a href=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/08\/NPR-logo.png\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-full wp-image-3902\" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/08\/NPR-logo.png\" alt=\"\" width=\"152\" height=\"55\" srcset=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/08\/NPR-logo.png 152w, https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/08\/NPR-logo-150x55.png 150w\" sizes=\"auto, (max-width: 152px) 100vw, 152px\" \/><\/a><\/p>\n<pre><strong>Notice:<\/strong> The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.<\/pre>\n","protected":false},"excerpt":{"rendered":"<p>(By Sydney Lupkin for NPR) Sometimes, the approval of a new generic drug offers more hype than hope for patients&#8217;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[21,15],"tags":[],"class_list":["post-15020","post","type-post","status-publish","format-standard","hentry","category-health-care-finance","category-part-dprescription-drugs"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/15020","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=15020"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/15020\/revisions"}],"predecessor-version":[{"id":15021,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/15020\/revisions\/15021"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=15020"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=15020"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=15020"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}